TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today that it ...
Avid Bioservices' stock plummeted 30% post-earnings; Q3 revenue fell 11%, with significant drops in gross margin and operating income. Announced planned $160 million 7.00% Convertible Senior Notes; ...
In connection with the closing of the transaction contemplated by the Merger Agreement, a Fundamental Change occurred under the Indenture on February 5, 2025, which is the effective date of such ...
Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today the pricing of $160 million aggregate principal amount of 7.00% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results